Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 4/20 | 0.60 |
| ▸ | MMP12 | P39900 | 2/20 | 0.60 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.60 |
| ▸ | MMP3 | P08254 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5887921 | 0.95 | MMP2 (0.56) | MMP2MMP12ADAM17MMP3MMP13 | |
| SCHEMBL5887880 | 0.88 | ADAM17 (0.62) | MMP2MMP12ADAM17MMP3MMP13 | |
| Trifluoroacetic Acid SCHEMBL5887714 | 0.83 | ADAM17 (0.57) | MMP2MMP12ADAM17MMP3MMP13 | |
| SCHEMBL5887512 | 0.80 | ADAM17 (0.57) | MMP2MMP12ADAM17MMP3MMP13 | |
| SCHEMBL4053406 | 0.79 | ADAM17 (0.65) | MMP2MMP12ADAM17MMP3MMP13 | |
| SCHEMBL4053652 | 0.79 | MMP2 (0.62) | MMP2MMP12ADAM17MMP3MMP13 | |
| SCHEMBL5887697 | 0.79 | ADAM17 (0.52) | MMP2ADAM17MMP13 | |
| SCHEMBL5887930 | 0.79 | ADAM17 (0.47) | MMP2MMP12ADAM17MMP13 | |
| SCHEMBL6100999 | 0.78 | MMP13 (0.63) | MMP2MMP12ADAM17MMP13 | |
| SCHEMBL4050948 | 0.78 | MMP2 (0.60) | MMP2MMP12ADAM17MMP3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041693-B2 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-09 | — | — | US | claimed |
| EP-1546109-A4 | HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME (TACE) | BRISTOL MYERS SQUIBB CO (US) | 2005-11-09 | — | — | EP | claimed |
| EP-1546109-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME (TACE) | Bristol-Myers Squibb Company (US) | 2005-06-29 | — | — | EP | claimed |
| WO-2004033632-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-22 | — | — | WO | claimed |
| US-20040067996-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067996-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAM17, ADAM9, ADAMTS1 | MMP2 13/4885MMP12 18/4885ADAM17 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.